Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-702X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials ; volume:252 ; number:10 ; day:22 ; month:8 ; year:2014 ; pages:1529-1537 ; date:10.2014
Graefe's archive for clinical and experimental ophthalmology ; 252, Heft 10 (22.8.2014), 1529-1537, 10.2014
- Creator
-
Kodjikian, Laurent
Decullier, Evelyne
Souied, Eric H.
Girmens, Jean-François
Durand, Emilie E.
Chapuis, François R.
Huot, Laure
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00417-014-2764-6
- URN
-
urn:nbn:de:101:1-2019080303175748167989
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kodjikian, Laurent
- Decullier, Evelyne
- Souied, Eric H.
- Girmens, Jean-François
- Durand, Emilie E.
- Chapuis, François R.
- Huot, Laure
- SpringerLink (Online service)
Other Objects (12)
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration
Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation